Article

Starting Indoor Tanning Early Linked to Melanoma Diagnoses in Younger Women

Author(s):

Younger melanoma patients undergo indoor tanning more frequently than older women with melanoma.

Younger women (below age 40) who are diagnosed with melanoma frequently report that they began indoor tanning at an earlier age.

Melanoma patients below 40 years of age were also found to undergo indoor tanning more frequently than older women with melanoma.

To analyze the relationship between melanoma diagnosis and indoor tanning, the age when indoor tanning began, and the frequency of indoor tanning for men and women depending on age of melanoma diagnosis, DeAnn Lazovich,PhD, University of Minnesota, and colleagues conducted a study that included 681 patients who were diagnosed with melanoma between 2004 and 2007 and 654 control patients between the ages of 25 and 49.

According to the study, women below age 40 reported beginning indoor tanning at 16, compared to women 40-49 who only started at 25. Additionally, the younger group reported more frequent tanning of 100 sessions compared t the 40 sessions of the older women.

The study results indicated women who practiced indoor tanning were two to six times more likely to develop melanoma.

The researchers found approximately 33% of the women diagnosed prior to 30 years of age had melanomas on their trunk compared to 24% of women who were between 40-49 years.

While men were less likely to report indoor tanning use compared to women, 41% men of the 30-39 age group were diagnosed with melanoma on their trunk compared with 49% of men between 40-49 years.

The study authors concluded, “Our results indicate that these efforts need to be accelerated and expanded beyond bans on minor access to indoor tanning to curb the melanoma epidemic, which seems to continue unabated especially among young women, unless exposure to indoor tanning is further restricted and reduced.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards